Skip to main content

Advertisement

Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer

Fig. 2

Comparative analysis of EET metabolite levels or CYP epoxygenase expressions may serve as potential bio- and histologic markers for TNBC. Box plots showing the concentration of the a EET isomers and the b EET/DHET ratios detected and quantified in breast cancer tumors (N = 62) classified according to hormone receptor status: TNBC (ER−/PR−/HER2−), HER2− (ER+/PR+/HER2-), HER2+ (ER−/PR−/HER2+) and TPBC (ER+/PR+/HER2+). All analyses include 4 technical replicates per biological sample. Error bars indicate mean ± SEM. Significantly different values (P = 0.05, ANOVA) are denoted by letters. c Representative strong positive, positive and weak positive/negative immunostaining results of IHC analyses for tumor sections (N = 55) obtained against CYP2J, CYP2C or sEH antibodies. DAB-staining was used to visualize immunoreactive regions and cellular nuclei (blue) were counterstained with hematoxylin. Images were taken at 40x magnification. d Quantitative scoring analyses of the immunostained tissues using IHC profiler shows the percentage contribution of DAB-stained cells with strong positive, positive and weak positive/negative immunoreactivity for CYP2J, CYP2C or CYP3A4 antibodies

Back to article page